HomeArticlesImpacting NewsThe U.S. FDA Approved BridgeBio Pharma Product Attruby to Treat Adults with ATTR-CM to Reduce Cardiovascular Death and Hospitalization
Impacting News
Premium

The U.S. FDA Approved BridgeBio Pharma Product Attruby to Treat Adults with ATTR-CM to Reduce Cardiovascular Death and Hospitalization

BridgeBio Pharma in the NEWS BridgeBio Pharma ( BBIO ) focused on genetic diseases, announced that the United States FDA approved Attruby™ (acoramidis), an orally administered near-complete stabilizer...
P

Prohost Biotech

1 min read
15
0

Unlock Premium Content

This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.

Unlimited articles
Expert analysis
Research reports

Comments (0)

Please sign in to join the discussion